View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsLiminal BioSciences 将来の成長Future 基準チェック /06現在、 Liminal BioSciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率-149.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日10 Apr 2023今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 28Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite IndexLiminal BioSciences Inc. has been removed from NASDAQ Composite Index .お知らせ • Sep 27+ 1 more updateStructured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a non-binding proposal to acquire remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) for $8.4 million on April 4, 2023. Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a a definitive arrangement agreement to acquire remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) for $10.7 million on July 11, 2023. Structured Alpha will pay $7.50 in cash per common share of Liminal BioSciences. SALP currently owns 1,987,622 common shares of Liminal Biosciences representing approximately 64.03% of the Liminal's currently outstanding common shares. A special committee of the independent members of the Board (the "Special Committee") has been formed and will evaluate the Proposal and any viable alternatives that may be available to Liminal. Under the terms of definitive agreement, Liminal BioSciences shareholders will receive $8.50 in cash per Common Share. A termination fee of $322,000 would be payable by Liminal BioSciences to Structured Alpha in certain circumstances. The proposed transaction would be conditioned on the receipt of customary approvals, including regulatory approvals, court approval, the receipt of Liminal BioSciences shareholder approvals required under applicable securities laws, including Multilateral Instrument 61-101 – Protection of Minority Security Holders in special transactions, and other conditions customary for a transaction of this nature, including confirmatory due diligence satisfactory to Thomvest. The transaction is not subject to any financing condition. Board of Directors of Liminal BioSciences have unanimously approved the transaction. The transaction is not subject to any financing condition. On August 16, 2023, the Ontario Superior Court of Justice approved the transaction. A special meeting of Liminal BioSciences will be held on September 15, 2023. As of September 15, 2023, the shareholders of Liminal BioSciences approved the transaction. The transaction is expected to close no later than September 30, 2023. As of September 15, 2023, the transaction is expected to close at or around the end of September 2023. As per the filling on September 19, 2023, Liminal BioSciences received the final order of the Ontario Superior Court of Justice and expected to close on or about September 26, 2023, subject to the satisfaction or waiver of certain other customary conditions precedent to the Arrangement. BMO Nesbitt Burns Inc. acted as financial advisor and fairness opinion provider to the special committee of Liminal BioSciences. Pierre-Yves Leduc and Julien Robitaille-Rodriguez of Stikeman Elliot LLP and Kevin Cooper and Richard Segal of Cooley LLP are serving as Liminal BioSciences' legal advisors. Langstaff & Co. is acting as financial advisor to Structured Alpha. John Emanoilidis, Adam Ibrahim, Jordan Wright, John Fabello, Chris Richter, Andrew Gray, Mile Kurta, Maija Fiorante, Edward Fan and Andrew Wong of Torys LLP is serving as legal advisors to Structured Alpha. Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) on September 26, 2023. As a result of the completion of the Arrangement, the Common Shares will no longer be listed on the Nasdaq Global Market.お知らせ • Jul 14Liminal Biosciences' Common Shares to Be Delisted from NasdaqLiminal BioSciences Inc. and Structured Alpha LP (SALP), a fund managed by Thomvest Asset Management Ltd. announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own. The transaction will be completed pursuant to a court-approved plan of arrangement under section 192 of the Canada Business Corporations Act and is subject to satisfaction of customary closing conditions, including (without limitation) court approval and the approval of the shareholders of Liminal BioSciences as further set out below. After completion of the transaction, Liminal BioSciences expects to no longer be subject to the reporting requirements of applicable Canadian securities legislation or the U.S. Securities Exchange Act of 1934, as amended, and its common shares will be delisted from Nasdaq.お知らせ • Feb 17Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price RequirementLiminal BioSciences Inc. announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market. The notice indicated that, as a result of the closing bid price of the Company's common stock having been $1.00 per share or greater for at least ten consecutive business days, from February 1, 2023 through February 14, 2023, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).お知らせ • Nov 10+ 1 more updateLiminal BioSciences Inc. Appoints Gary Bridger as Interim Chief ScientificLiminal BioSciences Inc. in addition to the appointment of Nicole as CFO, Dr. Gary Bridger, current member of the Board of Directors and Strategic Advisor to the Company, has been named Interim Chief Scientific Officer effective immediately. Dr. Bridger will oversee the Research and Development function and assume responsibility for leading all aspects of the Company's research and development programs. Dr. Bridger continues to serve as a board member of the Company.お知らせ • Nov 09Liminal BioSciences Inc. to Report Q3, 2022 Results on Nov 09, 2022Liminal BioSciences Inc. announced that they will report Q3, 2022 results at 8:00 PM, Central European Standard Time on Nov 09, 2022お知らせ • Sep 02Liminal Biosciences Announces Listing Transfer to The Nasdaq Capital Market from The Nasdaq Global MarketLiminal BioSciences Inc. announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the company's application to transfer its common shares from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810(c)(3)(A), had been approved. The Company's common shares will begin trading on The Nasdaq Capital Market effective at the start of trading on September 6, 2022. The Company's shares will continue to trade on Nasdaq under the symbol "LMNL". The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and companies on the Nasdaq Capital Market must meet certain financial and corporate governance requirements to qualify for continued listing. As previously disclosed on March 4, 2022, the Company had received a written notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules and had been granted a 180-day compliance period to comply with the minimum bid price requirement. In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the Company a second period of 180 calendar days, or until February 27, 2023, to regain compliance with the minimum bid price requirement for continued listing by achieving a closing bid price on Nasdaq of at least $1.00 per share for a minimum of ten consecutive trading days. Nasdaq's decision to approve the Company's application to transfer to The Nasdaq Capital Market was based on the Company meeting the listing requirements of The Nasdaq Capital Market with the exception of the minimum bid requirement. The Company provided Nasdaq with its written intent to cure the minimum bid price deficiency during the additional compliance period by implementing a reverse stock split, if necessary, prior to the expiration of the second compliance period. The Company intends to continue to actively monitor its compliance with the minimum closing bid price requirement and, evaluate available options to regain compliance.お知らせ • Aug 11Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30.Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30 on August 8, 2022. Under the terms of the transaction, Liminal BioSciences the remaining preferred and common shares in Pathogen Removal and Diagnostic Technologies. As a result of the transaction, Liminal BioSciences now owns 100% stake in Pathogen Removal and Diagnostic Technologies.Liminal BioSciences Inc. (DB:PJ2N) completed the acquisition of the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. on August 8, 2022.お知らせ • Jul 22Liminal BioSciences Inc. Announces Discontinuation of Fezagepras DevelopmentLiminal BioSciences Inc. announced that it has discontinued development of fezagepras. The decision to discontinue the development of fezagepras is based on results from the Phase 1a single ascending dose clinical trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The Phase 1a SAD clinical trial of fezagepras initiated in May 2022 was designed as a head-to-head comparison with Sodium Phenylbutyrate to provides with further data to determine whether fezagepras was worth developing for one of the potential indications where nitrogen scavenging is beneficial. The recommendation to stop the development program for fezagepras was not based on safety concerns.お知らせ • May 24Liminal Biosciences Announces First Subject Dosed in Phase 1A Single Ascending Dose Clinical Trial of FezageprasLiminal BioSciences Inc. announced that the first subject has been dosed in the Company's Phase 1a single ascending dose randomized, open label, cross over clinical trial of fezagepras to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose of fezagepras compared to Sodium Phenylbutyrate in healthy volunteers. Analysis of the disproportionate metabolite data from the completed Phase 1 multi-ascending dose ("MAD") clinical trial revealed that fezagepras's primary metabolite was a glutamine conjugate. Company believe that the conjugation of fezagepras with glutamine provides early evidence that fezagepras has the potential, subject to further research and clinical development, to act as a nitrogen scavenging drug with the potential to treat disorders associated with hyperammonaemia. Nitrogen scavenging drugs are used in the treatment of conditions characterized by hyperammonemia (high ammonia) and target to remove ammonia from the bloodstream by conjugating with glutamine or glycine with the resulted conjugated drug being excreted in the urine. The production of glutamine in humans requires ammonia. Ammonia is highly toxic and high levels may damage many organs including the brain. Toxic effects of hyperammonemia (high ammonia) can lead to confusion (encephalopathy), coma and if untreated, death.お知らせ • May 10Liminal BioSciences Inc. to Report Q1, 2022 Results on May 10, 2022Liminal BioSciences Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022お知らせ • Apr 02Liminal BioSciences Inc., Annual General Meeting, Jun 06, 2022Liminal BioSciences Inc., Annual General Meeting, Jun 06, 2022.お知らせ • Mar 10Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementLiminal BioSciences Inc. announced that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the last 30 consecutive business days from January 20, 2022 to March 3, 2022, the Company has failed to meet the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency, It is not a notice of imminent delisting, and it has no current immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. The Notice states that under Listing Rule 5810(c)(3)(A) the Company is provided with a period of 180 calendar days, or August 31, 2022, to regain compliance with the Listing Rules. To regain compliance with the Listing Rules, the Company's listed securities price must be at least $1.00 for a minimum of ten consecutive business days. In the event the Company does not regain compliance by August 31, 2022, the Company may be eligible for additional time to regain compliance or may face delisting. The Company intends to continue to monitor the closing bid price of its ordinary shares between now and August 31, 2022, and to evaluate its available options to regain compliance within the compliance period.お知らせ • Jan 28Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N) on January 27, 2022. The transaction is subject to finalization of due diligence investigations by the parties, the negotiation and execution of definitive transaction agreements and other customary closing conditions including certain funding requirements.お知らせ • Jun 24Kedrion S.p.A. signed a share purchase agreement to acquire Prometic Bioproduction Inc. and Prometic Biotherapeutics Inc. from Liminal BioSciences Inc. (DB:PJ2N).Kedrion S.p.A. signed a share purchase agreement to acquire Prometic Bioproduction Inc. and Prometic Biotherapeutics Inc. from Liminal BioSciences Inc. (DB:PJ2N) on June 23, 2021. Kedrion S.p.A. will pay $5 million for Prometic Bioproduction Inc. The transaction is subject to the fulfilment of the certain customary conditions precedent.お知らせ • Jun 05Liminal BioSciences Inc. Announces FDA Approval for its Biologics License Application for Ryplazim® (Plasminogen, Human-Tvmh)Liminal BioSciences Inc. announced that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder. The efficacy of Ryplazim® in pediatric and adult patients with plasminogen deficiency type 1 was evaluated in a single-arm, open-label clinical trial. A total of 15 patients who had a baseline plasminogen activity level between <5% and 45% of normal were enrolled. All patients received Ryplazim® at a dose of 6.6 mg/kg administered every two to four days for 48 weeks to achieve at least an increase of individual trough plasminogen activity by an absolute 10% above baseline and to treat the clinical manifestations of the disease. Ryplazim® was well tolerated in the clinical study (See Important Safety Information). Efficacy was established on the basis of overall rate of clinical success at 48 weeks defined as 50% of patients with visible or other measurable non-visible lesions achieving at least 50% improvement in lesion number/size, or functionality impact from baseline. All patients with any lesion at baseline showed at least 50% improvement in the number or size of their lesions. In all patients with plasminogen deficiency, plasma plasminogen levels are markedly reduced. Plasminogen is a naturally occurring protein that is synthesized by the liver and circulates in the blood. Activated plasminogen, known as plasmin, is an enzymatic component of the fibrinolytic system and the main enzyme involved in the lysis of clots and clearance of extravasated fibrin. As part of the sale of Liminal BioSciences' plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York in May 2021, Liminal BioSciences entered into an option agreement with Kedrion S.p.A. (Kedrion) pursuant to which Kedrion has the right to acquire the remainder of Liminal BioSciences' plasma-derived therapeutics' business, including the Ryplazim® business, for an exercise price of $5 million and would entitle Liminal BioSciences to receive up to 70% of the net proceeds which may be received from the sale of a PRV. Ryplazim® was previously granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for the treatment of congenital plasminogen deficiency. With this approval, the FDA issued a PRV to Liminal BioSciences Inc., through its subsidiary Prometic Biotherapeutics Inc., holder of the BLA. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.お知らせ • May 29Liminal BioSciences Inc. Provides an Update on Currently Planned Clinical Activities for FezageprasLiminal BioSciences Inc. announced that based on interim pharmacokinetic ("PK") results from the ongoing fezagepras multiple ascending dose (MAD) study, the company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, as it evaluates the impact of the PK data profile observed in the on-going study. The company is continuing to evaluate the interim PK results. Once the MAD study is complete, the Company expects that a full analysis of the complete PK data set from the phase 1 study will help determine the choice of any other potential indication for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the MAD study to date.お知らせ • Jan 29Liminal BioSciences Inc. Provides an Update Regarding the Company’s Corporate Strategy for Its Small Molecule Therapeutics and Plasma-Derived Based Therapeutics PlatformsLiminal BioSciences Inc. provided an update regarding the Company’s corporate strategy for its small molecule therapeutics and plasma-derived based therapeutics platforms. Following a review of its corporate business strategy, aimed at maximizing the use of capital resources, the Company has decided to re-focus its resources on its small molecule therapeutics business. It has therefore determined that its plasma-derived therapeutics business is no longer aligned with this new corporate business strategy. As previously disclosed, the Company has been engaged in a process to find a commercialization partner for Ryplazim® (plasminogen) (“Ryplazim”), which has to date not resulted in an executable transaction. As a consequence, and considering the ongoing cash burn associated with the plasma-derived therapeutics business, the Company announced that it has commenced a process to evaluate potential strategic alternatives for that portion of its business aimed at minimizing cash burn. These alternatives may result in a divestment, in whole or in part, of the plasma-derived therapeutics business and/or other non-core assets, or in other courses of action including but not limited to other strategic transactions or the closure of its Ryplazim related operations. The Company believes that such change in its business strategy will allow it to become more streamlined and with a singular focus on its core research capabilities and emerging pipeline.お知らせ • Dec 17Liminal BioSciences Inc. Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of FezageprasLiminal BioSciences Inc. announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide selection of the appropriate dose and dosing frequency of fezagepras for anticipated future clinical trials. Fezagepras is an anti-inflammatory and anti-fibrotic small molecule designed to modulate the activity of multiple receptors, including FFAR1 (GPR40) and PPAR alpha. Both FFAR1 and PPAR alpha have been shown to have an impact on metabolic control and to play a role in the pathogenesis of diseases including NAFLD and NASH. Further, third-party data suggests that FFAR1 plays a role in glucose control, while PPAR alpha appears to modulate lipids. Given their long association with the control of metabolic disease and the association between metabolic and fibrotic processes, the PPAR agonist class has a strong development rationale in fibrotic disease.お知らせ • Nov 13+ 1 more updateLiminal BioSciences Inc. Announces Executive ChangesOn November 12, 2020, the Liminal BioSciences Inc. announced that Mr. Kenneth Galbraith tendered his resignation as Chief Executive Officer and member of its Board for personal reasons, effective November 13, 2020. Mr. Bruce Pritchard, Chief Operating Officer, Small Molecules Therapeutics, and Mr. Patrick Sartore, Chief Operating Officer, Plasma-Derived Therapeutics, will assume the roles of Chief Executive Officer and President, respectively, effective November 13, 2020.お知らせ • Nov 09Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLALiminal BioSciences Inc. announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has extended the review period for the Biologics License Application ("BLA") for Ryplazim® (plasminogen), or Ryplazim, for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency ("C-PLGD"). The new Prescription Drug User Fee Act (PDUFA) target action date has been extended by the FDA by three months to June 5, 2021. The BLA resubmission for Ryplazim was originally accepted by FDA in September 2020 as a Class 2 response to the prior complete response letter issued by FDA in 2018, with a six-month review period, and the FDA set a PDUFA target action date of March 5, 2021. The Company recently submitted a response to an information request from the FDA related to the BLA resubmission. On November 6, 2020, the FDA notified that the submission of this additional information by the Company constituted a major amendment because the submission contained substantial new manufacturing or facility information not previously submitted to or reviewed by the FDA, which entitles FDA to extend the review process by three months. The new PDUFA target action date is now June 5, 2021. The BLA resubmission for Ryplazim® was supported by data from a Phase 2/3 clinical trial, which evaluated 15 patients, both pediatric and adults, with C-PLGD over 48 weeks of therapy with Ryplazim®.お知らせ • Nov 07Liminal BioSciences Inc. to Report Q3, 2020 Results on Nov 12, 2020Liminal BioSciences Inc. announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 12, 2020お知らせ • Jul 23Liminal BioSciences to Voluntarily Delist from the Toronto Stock ExchangeLiminal BioSciences Inc. announced that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020. Since the Company's Common Shares started trading on the Nasdaq Global Market ("NASDAQ") in the fourth quarter of 2019, the vast majority of active daily trading has shifted from the TSX to NASDAQ. After conducting a thorough evaluation of its dual listing, considering such factors as overall liquidity, costs, regulatory compliance and complexity, the Company believes that the financial and administrative costs associated with maintaining a dual listing are no longer justified.お知らせ • Jul 18Liminal BioSciences Inc. announced that it has received CAD 2.4 million in funding from Amorchem, Genesys Capital Partners Inc.Liminal BioSciences Inc. (TSX:LMNL) announced a private placement of secured convertible debentures for gross proceeds of CAD 2,400,000 on July 17, 2020. The debentures bear an interest rate of 8% per annum, computed quarterly and will mature on March 31, 2022. The transaction included participation from Amorchem, AmorChem II, a fund managed by Amorchem, and Genesys Capital Partners Inc. The debentures may be converted into common shares at the option of the company, or at the option of the debenture holders. The debentures are issued at par.業績と収益の成長予測DB:PJ2 - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024N/AN/AN/AN/A112/31/2023N/AN/AN/AN/A112/31/20220-29-32-32N/A9/30/20220-31-38-38N/A6/30/20221-35-84-84N/A3/31/20220-42-86-86N/A12/31/20211-44-100-100N/A9/30/20211-48-114-114N/A6/30/20211-49-75-74N/A3/31/20211-35-75-74N/A12/31/20201-48-78-76N/A9/30/20201-75-87-85N/A6/30/20202-94-86-85N/A3/31/20203-232-109-105N/A12/31/20191-150-104-99N/A9/30/2019-8-299-95-89N/A6/30/20193-298-90-84N/A3/31/201923-194-73-68N/A12/31/201825-197-88-82N/A9/30/201843-131-91-85N/A6/30/201855-118-112-105N/A3/31/201839-115-128-120N/A12/31/201722-112-133-123N/A9/30/201737-109-139-129N/A6/30/201716-119-130-118N/A3/31/201716-112-127-114N/A12/31/201616-101-113-98N/A9/30/201626-74N/A-76N/A6/30/201628-58N/A-66N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PJ2の予測収益成長が 貯蓄率 ( 0.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PJ2の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PJ2の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PJ2来年は収益がないと予測されています。高い収益成長: PJ2来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PJ2の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/05/02 08:02終値2023/02/02 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Liminal BioSciences Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Doug CooperBeacon Securities LimitedAntonia BorovinaBloom Burton & Co.Dewey SteadmanCanaccord Genuity9 その他のアナリストを表示
お知らせ • Sep 28Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite IndexLiminal BioSciences Inc. has been removed from NASDAQ Composite Index .
お知らせ • Sep 27+ 1 more updateStructured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a non-binding proposal to acquire remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) for $8.4 million on April 4, 2023. Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. entered into a a definitive arrangement agreement to acquire remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) for $10.7 million on July 11, 2023. Structured Alpha will pay $7.50 in cash per common share of Liminal BioSciences. SALP currently owns 1,987,622 common shares of Liminal Biosciences representing approximately 64.03% of the Liminal's currently outstanding common shares. A special committee of the independent members of the Board (the "Special Committee") has been formed and will evaluate the Proposal and any viable alternatives that may be available to Liminal. Under the terms of definitive agreement, Liminal BioSciences shareholders will receive $8.50 in cash per Common Share. A termination fee of $322,000 would be payable by Liminal BioSciences to Structured Alpha in certain circumstances. The proposed transaction would be conditioned on the receipt of customary approvals, including regulatory approvals, court approval, the receipt of Liminal BioSciences shareholder approvals required under applicable securities laws, including Multilateral Instrument 61-101 – Protection of Minority Security Holders in special transactions, and other conditions customary for a transaction of this nature, including confirmatory due diligence satisfactory to Thomvest. The transaction is not subject to any financing condition. Board of Directors of Liminal BioSciences have unanimously approved the transaction. The transaction is not subject to any financing condition. On August 16, 2023, the Ontario Superior Court of Justice approved the transaction. A special meeting of Liminal BioSciences will be held on September 15, 2023. As of September 15, 2023, the shareholders of Liminal BioSciences approved the transaction. The transaction is expected to close no later than September 30, 2023. As of September 15, 2023, the transaction is expected to close at or around the end of September 2023. As per the filling on September 19, 2023, Liminal BioSciences received the final order of the Ontario Superior Court of Justice and expected to close on or about September 26, 2023, subject to the satisfaction or waiver of certain other customary conditions precedent to the Arrangement. BMO Nesbitt Burns Inc. acted as financial advisor and fairness opinion provider to the special committee of Liminal BioSciences. Pierre-Yves Leduc and Julien Robitaille-Rodriguez of Stikeman Elliot LLP and Kevin Cooper and Richard Segal of Cooley LLP are serving as Liminal BioSciences' legal advisors. Langstaff & Co. is acting as financial advisor to Structured Alpha. John Emanoilidis, Adam Ibrahim, Jordan Wright, John Fabello, Chris Richter, Andrew Gray, Mile Kurta, Maija Fiorante, Edward Fan and Andrew Wong of Torys LLP is serving as legal advisors to Structured Alpha. Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2) on September 26, 2023. As a result of the completion of the Arrangement, the Common Shares will no longer be listed on the Nasdaq Global Market.
お知らせ • Jul 14Liminal Biosciences' Common Shares to Be Delisted from NasdaqLiminal BioSciences Inc. and Structured Alpha LP (SALP), a fund managed by Thomvest Asset Management Ltd. announced that they have entered into a definitive arrangement agreement (the "Arrangement Agreement") under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Common Shares") that it does not already own. The transaction will be completed pursuant to a court-approved plan of arrangement under section 192 of the Canada Business Corporations Act and is subject to satisfaction of customary closing conditions, including (without limitation) court approval and the approval of the shareholders of Liminal BioSciences as further set out below. After completion of the transaction, Liminal BioSciences expects to no longer be subject to the reporting requirements of applicable Canadian securities legislation or the U.S. Securities Exchange Act of 1934, as amended, and its common shares will be delisted from Nasdaq.
お知らせ • Feb 17Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price RequirementLiminal BioSciences Inc. announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market. The notice indicated that, as a result of the closing bid price of the Company's common stock having been $1.00 per share or greater for at least ten consecutive business days, from February 1, 2023 through February 14, 2023, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).
お知らせ • Nov 10+ 1 more updateLiminal BioSciences Inc. Appoints Gary Bridger as Interim Chief ScientificLiminal BioSciences Inc. in addition to the appointment of Nicole as CFO, Dr. Gary Bridger, current member of the Board of Directors and Strategic Advisor to the Company, has been named Interim Chief Scientific Officer effective immediately. Dr. Bridger will oversee the Research and Development function and assume responsibility for leading all aspects of the Company's research and development programs. Dr. Bridger continues to serve as a board member of the Company.
お知らせ • Nov 09Liminal BioSciences Inc. to Report Q3, 2022 Results on Nov 09, 2022Liminal BioSciences Inc. announced that they will report Q3, 2022 results at 8:00 PM, Central European Standard Time on Nov 09, 2022
お知らせ • Sep 02Liminal Biosciences Announces Listing Transfer to The Nasdaq Capital Market from The Nasdaq Global MarketLiminal BioSciences Inc. announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the company's application to transfer its common shares from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810(c)(3)(A), had been approved. The Company's common shares will begin trading on The Nasdaq Capital Market effective at the start of trading on September 6, 2022. The Company's shares will continue to trade on Nasdaq under the symbol "LMNL". The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and companies on the Nasdaq Capital Market must meet certain financial and corporate governance requirements to qualify for continued listing. As previously disclosed on March 4, 2022, the Company had received a written notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules and had been granted a 180-day compliance period to comply with the minimum bid price requirement. In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the Company a second period of 180 calendar days, or until February 27, 2023, to regain compliance with the minimum bid price requirement for continued listing by achieving a closing bid price on Nasdaq of at least $1.00 per share for a minimum of ten consecutive trading days. Nasdaq's decision to approve the Company's application to transfer to The Nasdaq Capital Market was based on the Company meeting the listing requirements of The Nasdaq Capital Market with the exception of the minimum bid requirement. The Company provided Nasdaq with its written intent to cure the minimum bid price deficiency during the additional compliance period by implementing a reverse stock split, if necessary, prior to the expiration of the second compliance period. The Company intends to continue to actively monitor its compliance with the minimum closing bid price requirement and, evaluate available options to regain compliance.
お知らせ • Aug 11Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30.Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30 on August 8, 2022. Under the terms of the transaction, Liminal BioSciences the remaining preferred and common shares in Pathogen Removal and Diagnostic Technologies. As a result of the transaction, Liminal BioSciences now owns 100% stake in Pathogen Removal and Diagnostic Technologies.Liminal BioSciences Inc. (DB:PJ2N) completed the acquisition of the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. on August 8, 2022.
お知らせ • Jul 22Liminal BioSciences Inc. Announces Discontinuation of Fezagepras DevelopmentLiminal BioSciences Inc. announced that it has discontinued development of fezagepras. The decision to discontinue the development of fezagepras is based on results from the Phase 1a single ascending dose clinical trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The Phase 1a SAD clinical trial of fezagepras initiated in May 2022 was designed as a head-to-head comparison with Sodium Phenylbutyrate to provides with further data to determine whether fezagepras was worth developing for one of the potential indications where nitrogen scavenging is beneficial. The recommendation to stop the development program for fezagepras was not based on safety concerns.
お知らせ • May 24Liminal Biosciences Announces First Subject Dosed in Phase 1A Single Ascending Dose Clinical Trial of FezageprasLiminal BioSciences Inc. announced that the first subject has been dosed in the Company's Phase 1a single ascending dose randomized, open label, cross over clinical trial of fezagepras to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose of fezagepras compared to Sodium Phenylbutyrate in healthy volunteers. Analysis of the disproportionate metabolite data from the completed Phase 1 multi-ascending dose ("MAD") clinical trial revealed that fezagepras's primary metabolite was a glutamine conjugate. Company believe that the conjugation of fezagepras with glutamine provides early evidence that fezagepras has the potential, subject to further research and clinical development, to act as a nitrogen scavenging drug with the potential to treat disorders associated with hyperammonaemia. Nitrogen scavenging drugs are used in the treatment of conditions characterized by hyperammonemia (high ammonia) and target to remove ammonia from the bloodstream by conjugating with glutamine or glycine with the resulted conjugated drug being excreted in the urine. The production of glutamine in humans requires ammonia. Ammonia is highly toxic and high levels may damage many organs including the brain. Toxic effects of hyperammonemia (high ammonia) can lead to confusion (encephalopathy), coma and if untreated, death.
お知らせ • May 10Liminal BioSciences Inc. to Report Q1, 2022 Results on May 10, 2022Liminal BioSciences Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022
お知らせ • Apr 02Liminal BioSciences Inc., Annual General Meeting, Jun 06, 2022Liminal BioSciences Inc., Annual General Meeting, Jun 06, 2022.
お知らせ • Mar 10Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementLiminal BioSciences Inc. announced that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the last 30 consecutive business days from January 20, 2022 to March 3, 2022, the Company has failed to meet the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency, It is not a notice of imminent delisting, and it has no current immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. The Notice states that under Listing Rule 5810(c)(3)(A) the Company is provided with a period of 180 calendar days, or August 31, 2022, to regain compliance with the Listing Rules. To regain compliance with the Listing Rules, the Company's listed securities price must be at least $1.00 for a minimum of ten consecutive business days. In the event the Company does not regain compliance by August 31, 2022, the Company may be eligible for additional time to regain compliance or may face delisting. The Company intends to continue to monitor the closing bid price of its ordinary shares between now and August 31, 2022, and to evaluate its available options to regain compliance within the compliance period.
お知らせ • Jan 28Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N) on January 27, 2022. The transaction is subject to finalization of due diligence investigations by the parties, the negotiation and execution of definitive transaction agreements and other customary closing conditions including certain funding requirements.
お知らせ • Jun 24Kedrion S.p.A. signed a share purchase agreement to acquire Prometic Bioproduction Inc. and Prometic Biotherapeutics Inc. from Liminal BioSciences Inc. (DB:PJ2N).Kedrion S.p.A. signed a share purchase agreement to acquire Prometic Bioproduction Inc. and Prometic Biotherapeutics Inc. from Liminal BioSciences Inc. (DB:PJ2N) on June 23, 2021. Kedrion S.p.A. will pay $5 million for Prometic Bioproduction Inc. The transaction is subject to the fulfilment of the certain customary conditions precedent.
お知らせ • Jun 05Liminal BioSciences Inc. Announces FDA Approval for its Biologics License Application for Ryplazim® (Plasminogen, Human-Tvmh)Liminal BioSciences Inc. announced that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics Inc., holder of the biological license application ("BLA") for Ryplazim®. With this approval, Ryplazim® becomes the first FDA approved therapy for this rare genetic disorder. The efficacy of Ryplazim® in pediatric and adult patients with plasminogen deficiency type 1 was evaluated in a single-arm, open-label clinical trial. A total of 15 patients who had a baseline plasminogen activity level between <5% and 45% of normal were enrolled. All patients received Ryplazim® at a dose of 6.6 mg/kg administered every two to four days for 48 weeks to achieve at least an increase of individual trough plasminogen activity by an absolute 10% above baseline and to treat the clinical manifestations of the disease. Ryplazim® was well tolerated in the clinical study (See Important Safety Information). Efficacy was established on the basis of overall rate of clinical success at 48 weeks defined as 50% of patients with visible or other measurable non-visible lesions achieving at least 50% improvement in lesion number/size, or functionality impact from baseline. All patients with any lesion at baseline showed at least 50% improvement in the number or size of their lesions. In all patients with plasminogen deficiency, plasma plasminogen levels are markedly reduced. Plasminogen is a naturally occurring protein that is synthesized by the liver and circulates in the blood. Activated plasminogen, known as plasmin, is an enzymatic component of the fibrinolytic system and the main enzyme involved in the lysis of clots and clearance of extravasated fibrin. As part of the sale of Liminal BioSciences' plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York in May 2021, Liminal BioSciences entered into an option agreement with Kedrion S.p.A. (Kedrion) pursuant to which Kedrion has the right to acquire the remainder of Liminal BioSciences' plasma-derived therapeutics' business, including the Ryplazim® business, for an exercise price of $5 million and would entitle Liminal BioSciences to receive up to 70% of the net proceeds which may be received from the sale of a PRV. Ryplazim® was previously granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for the treatment of congenital plasminogen deficiency. With this approval, the FDA issued a PRV to Liminal BioSciences Inc., through its subsidiary Prometic Biotherapeutics Inc., holder of the BLA. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.
お知らせ • May 29Liminal BioSciences Inc. Provides an Update on Currently Planned Clinical Activities for FezageprasLiminal BioSciences Inc. announced that based on interim pharmacokinetic ("PK") results from the ongoing fezagepras multiple ascending dose (MAD) study, the company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, as it evaluates the impact of the PK data profile observed in the on-going study. The company is continuing to evaluate the interim PK results. Once the MAD study is complete, the Company expects that a full analysis of the complete PK data set from the phase 1 study will help determine the choice of any other potential indication for further development of fezagepras. No dose-limiting adverse events or other potential safety signals have been observed in the MAD study to date.
お知らせ • Jan 29Liminal BioSciences Inc. Provides an Update Regarding the Company’s Corporate Strategy for Its Small Molecule Therapeutics and Plasma-Derived Based Therapeutics PlatformsLiminal BioSciences Inc. provided an update regarding the Company’s corporate strategy for its small molecule therapeutics and plasma-derived based therapeutics platforms. Following a review of its corporate business strategy, aimed at maximizing the use of capital resources, the Company has decided to re-focus its resources on its small molecule therapeutics business. It has therefore determined that its plasma-derived therapeutics business is no longer aligned with this new corporate business strategy. As previously disclosed, the Company has been engaged in a process to find a commercialization partner for Ryplazim® (plasminogen) (“Ryplazim”), which has to date not resulted in an executable transaction. As a consequence, and considering the ongoing cash burn associated with the plasma-derived therapeutics business, the Company announced that it has commenced a process to evaluate potential strategic alternatives for that portion of its business aimed at minimizing cash burn. These alternatives may result in a divestment, in whole or in part, of the plasma-derived therapeutics business and/or other non-core assets, or in other courses of action including but not limited to other strategic transactions or the closure of its Ryplazim related operations. The Company believes that such change in its business strategy will allow it to become more streamlined and with a singular focus on its core research capabilities and emerging pipeline.
お知らせ • Dec 17Liminal BioSciences Inc. Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of FezageprasLiminal BioSciences Inc. announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new clinical trial is designed to look at more frequent daily dosing (twice and three times daily) of fezagepras up to 2,400mg for a total of 14 days. The clinical trial is a standard placebo-controlled Phase 1 ascending dose design in healthy volunteers. The clinical trial endpoints will include safety, pharmacokinetics, and exploratory biomarkers related to the mechanism of action of fezagepras. The data from this clinical trial will be used to guide selection of the appropriate dose and dosing frequency of fezagepras for anticipated future clinical trials. Fezagepras is an anti-inflammatory and anti-fibrotic small molecule designed to modulate the activity of multiple receptors, including FFAR1 (GPR40) and PPAR alpha. Both FFAR1 and PPAR alpha have been shown to have an impact on metabolic control and to play a role in the pathogenesis of diseases including NAFLD and NASH. Further, third-party data suggests that FFAR1 plays a role in glucose control, while PPAR alpha appears to modulate lipids. Given their long association with the control of metabolic disease and the association between metabolic and fibrotic processes, the PPAR agonist class has a strong development rationale in fibrotic disease.
お知らせ • Nov 13+ 1 more updateLiminal BioSciences Inc. Announces Executive ChangesOn November 12, 2020, the Liminal BioSciences Inc. announced that Mr. Kenneth Galbraith tendered his resignation as Chief Executive Officer and member of its Board for personal reasons, effective November 13, 2020. Mr. Bruce Pritchard, Chief Operating Officer, Small Molecules Therapeutics, and Mr. Patrick Sartore, Chief Operating Officer, Plasma-Derived Therapeutics, will assume the roles of Chief Executive Officer and President, respectively, effective November 13, 2020.
お知らせ • Nov 09Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLALiminal BioSciences Inc. announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has extended the review period for the Biologics License Application ("BLA") for Ryplazim® (plasminogen), or Ryplazim, for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency ("C-PLGD"). The new Prescription Drug User Fee Act (PDUFA) target action date has been extended by the FDA by three months to June 5, 2021. The BLA resubmission for Ryplazim was originally accepted by FDA in September 2020 as a Class 2 response to the prior complete response letter issued by FDA in 2018, with a six-month review period, and the FDA set a PDUFA target action date of March 5, 2021. The Company recently submitted a response to an information request from the FDA related to the BLA resubmission. On November 6, 2020, the FDA notified that the submission of this additional information by the Company constituted a major amendment because the submission contained substantial new manufacturing or facility information not previously submitted to or reviewed by the FDA, which entitles FDA to extend the review process by three months. The new PDUFA target action date is now June 5, 2021. The BLA resubmission for Ryplazim® was supported by data from a Phase 2/3 clinical trial, which evaluated 15 patients, both pediatric and adults, with C-PLGD over 48 weeks of therapy with Ryplazim®.
お知らせ • Nov 07Liminal BioSciences Inc. to Report Q3, 2020 Results on Nov 12, 2020Liminal BioSciences Inc. announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 12, 2020
お知らせ • Jul 23Liminal BioSciences to Voluntarily Delist from the Toronto Stock ExchangeLiminal BioSciences Inc. announced that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020. Since the Company's Common Shares started trading on the Nasdaq Global Market ("NASDAQ") in the fourth quarter of 2019, the vast majority of active daily trading has shifted from the TSX to NASDAQ. After conducting a thorough evaluation of its dual listing, considering such factors as overall liquidity, costs, regulatory compliance and complexity, the Company believes that the financial and administrative costs associated with maintaining a dual listing are no longer justified.
お知らせ • Jul 18Liminal BioSciences Inc. announced that it has received CAD 2.4 million in funding from Amorchem, Genesys Capital Partners Inc.Liminal BioSciences Inc. (TSX:LMNL) announced a private placement of secured convertible debentures for gross proceeds of CAD 2,400,000 on July 17, 2020. The debentures bear an interest rate of 8% per annum, computed quarterly and will mature on March 31, 2022. The transaction included participation from Amorchem, AmorChem II, a fund managed by Amorchem, and Genesys Capital Partners Inc. The debentures may be converted into common shares at the option of the company, or at the option of the debenture holders. The debentures are issued at par.